Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovarijske neoplazme - antineoplastična sredstva - ciste na cancerlynparza je označen kot monotherapy za:vzdrževanje zdravljenje odraslih bolnikov z napredovalim (figo fazah iii in iv) brca1/2-mutiral (germline in/ali somatski) high-grade epitelnih jajčnikov, fallopian tube ali primarni trebušno raka, ki so v odziv (popolna ali delna) po koncu prve vrstice platinum, ki temelji kemoterapijo. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 in 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. bolniki morajo imeti predhodno že bili zdravljeni z anthracycline in taxane v (neo)adjuvant ali metastatskim nastavitev, če bolniki niso bili primerni za temi postopki (glej točko 5. bolniki z hormon receptorjev (hr)-pozitivnega raka dojk, je treba tudi napredovala na ali po predhodnem endokrine terapije, ali neprimerna za endokrine terapija. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - metformin hidroklorid, dapagliflozin propanediol monohidrat - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo je navedeno pri odraslih za zdravljenje diabetesa tipa 2 bolezni, kot dodatek k prehrani in izvajanje:• pri bolnikih, premalo nadzorovana na njihovo maksimalno dopustne odmerek metforminom sam • v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni pri bolnikih zadostno nadzorovana z metforminom in teh zdravil• pri bolnikih, ki se že zdravijo z kombinacijo dapagliflozin in metforminom kot ločene tablete. za študijski rezultati glede kombinacija terapij, vplivi na glycaemic nadzor in srčno-žilne dogodke, in populacije, ki je študiral glej poglavji 4. 4, 4. 5 in 5.

Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - zdravila za obstruktivne pljučne bolezni, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Slovėnija - slovėnų - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 160 µg / 1 odmerek  formoterolijev fumarat dihidrat4,5 µg / 1 odmerek; formoterolijev fumarat dihidrat 4,5 µg / 1 odmerek - formoterol in budezonid

Slovėnija - slovėnų - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 80 µg / 1 odmerek  formoterolijev fumarat dihidrat4,5 µg / 1 odmerek; formoterolijev fumarat dihidrat 4,5 µg / 1 odmerek - formoterol in budezonid

Slovėnija - slovėnų - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astrazeneca uk limited - tamoksifen - filmsko obložena tableta - tamoksifen 10 mg / 1 tableta - tamoksifen

Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - pljučna bolezen, kronična obstruktivna bolezen - formoterol in glycopyrronium bromid - bevespi aerosphere je označen kot vzdrževanje bronchodilator zdravljenje za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno bolezen (kopb).

Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pljučna bolezen, kronična obstruktivna bolezen - zdravila za obstruktivne pljučne bolezni, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pljučna bolezen, kronična obstruktivna bolezen - zdravila za obstruktivne pljučne bolezni, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Europos Sąjunga - slovėnų - EMA (European Medicines Agency)

astrazeneca ab - eksenatid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - byetta je indiciran za zdravljenje tipa 2 sladkorna bolezen v kombinaciji z:metformin;sulphonylureas;thiazolidinediones;metforminom in sulfonil sečnine;metforminom in thiazolidinedione;pri odraslih, ki niso dosegli ustreznega glycaemic nadzor na maksimalno dopustne koncentracije teh ustni terapije. byetta je prikazano tudi kot adjunctive terapija za bazalni insulin z ali brez metforminom in / ali pioglitazone pri odraslih, ki niso dosegli ustreznega glycaemic nadzor s temi zdravili.